Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients.

Mata-Marín JA, Smeke AE, Rodriguez MR, Chávez-García M, Banda-Lara MI, Rios AM, Nuñez-Rodríguez N, Domínguez-Hermosillo JC, Sánchez AC, Juarez-Kasusky I, Herrera JE, Ramírez JL, Gaytán-Martínez J.

Drugs R D. 2017 Mar;17(1):225-231. doi: 10.1007/s40268-017-0174-z.

2.

Views on HPV and HPV Vaccination: The Experience at a Federal Qualified Clinic in Puerto Rico.

Colón-López V, Toro-Mejías LM, Conde-Toro A, Serra-Rivera MJ, Martínez TM, Rodríguez V, Ríos AM, Berdiel L, Villanueva H.

J Health Care Poor Underserved. 2016;27(3):1411-26. doi: 10.1353/hpu.2016.0126.

3.

Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial.

Shiffman ML, Cheinquer H, Berg CP, Berg T, de Figueiredo-Mendes C, Dore GJ, Ferraz ML, Mendes-Corrêa MC, Lima MP, Parise ER, Rios AM, Reuter T, Sanyal AJ, Shafran SD, Hohmann M, Tatsch F, Bakalos G, Zeuzem S.

Hepatol Int. 2014 Oct;8(4):517-26. doi: 10.1007/s12072-014-9555-3. Epub 2014 Jul 24.

PMID:
26202757
4.

Bone marrow edema patterns in the ankle and hindfoot: distinguishing MRI features.

Rios AM, Rosenberg ZS, Bencardino JT, Rodrigo SP, Theran SG.

AJR Am J Roentgenol. 2011 Oct;197(4):W720-9. doi: 10.2214/AJR.10.5880. Review.

PMID:
21940545
5.

Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial.

Fonseca-Aten M, Okada PJ, Bowlware KL, Chavez-Bueno S, Mejias A, Rios AM, Katz K, Olsen K, Ng S, Jafri HS, McCracken GH, Ramilo O, Hardy RD.

Ann Allergy Asthma Immunol. 2006 Oct;97(4):457-63.

PMID:
17069099
6.

Treatment of experimental chronic pulmonary mycoplasmosis.

Fonseca-Aten M, Rios AM, Mejias A, Chavez-Bueno S, Katz K, Gomez AM, Ramilo O, McCracken GH, Hardy RD.

Int J Antimicrob Agents. 2006 Sep;28(3):253-8. Epub 2006 Aug 7.

PMID:
16891098
7.

Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency.

Mejías A, Chávez-Bueno S, Ríos AM, Aten MF, Raynor B, Peromingo E, Soni P, Olsen KD, Kiener PA, Gómez AM, Jafri HS, Ramilo O.

Antimicrob Agents Chemother. 2005 Nov;49(11):4700-7.

8.

Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.

Fonseca-Aten M, Salvatore CM, Mejías A, Ríos AM, Chávez-Bueno S, Katz K, Gómez AM, McCracken GH Jr, Hardy RD.

Antimicrob Agents Chemother. 2005 Oct;49(10):4128-36.

9.

Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.

Ríos AM, Fonseca-Aten M, Mejías A, Chávez-Bueno S, Katz K, Gómez AM, McCracken GH Jr, Ramilo O, Hardy RD.

Antimicrob Agents Chemother. 2005 Sep;49(9):3970-3.

10.

Respiratory syncytial virus-induced acute and chronic airway disease is independent of genetic background: an experimental murine model.

Chávez-Bueno S, Mejías A, Gómez AM, Olsen KD, Ríos AM, Fonseca-Aten M, Ramilo O, Jafri HS.

Virol J. 2005 May 25;2:46.

11.

Mycoplasma pneumoniae induces host-dependent pulmonary inflammation and airway obstruction in mice.

Fonseca-Aten M, Ríos AM, Mejías A, Chávez-Bueno S, Katz K, Gómez AM, McCracken GH Jr, Hardy RD.

Am J Respir Cell Mol Biol. 2005 Mar;32(3):201-10. Epub 2004 Dec 30.

PMID:
15626776
12.

[Asthma and respiratory syncytial virus. New opportunities for therapeutic intervention].

Mejías A, Chávez-Bueno S, Ríos AM, Fonseca-Aten M, Gómez AM, Jafri HS, Ramilo O.

An Pediatr (Barc). 2004 Sep;61(3):252-60. Review. Spanish.

13.

Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection.

Ríos AM, Mejías A, Chávez-Bueno S, Fonseca-Aten M, Katz K, Hatfield J, Gómez AM, Jafri HS, McCracken GH Jr, Ramilo O, Hardy RD.

Antimicrob Agents Chemother. 2004 Aug;48(8):2897-904.

14.

Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice.

Jafri HS, Chavez-Bueno S, Mejias A, Gomez AM, Rios AM, Nassi SS, Yusuf M, Kapur P, Hardy RD, Hatfield J, Rogers BB, Krisher K, Ramilo O.

J Infect Dis. 2004 May 15;189(10):1856-65. Epub 2004 Apr 29.

PMID:
15122522
15.

Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model.

Mejías A, Chávez-Bueno S, Ríos AM, Saavedra-Lozano J, Fonseca Aten M, Hatfield J, Kapur P, Gómez AM, Jafri HS, Ramilo O.

Antimicrob Agents Chemother. 2004 May;48(5):1811-22.

16.

Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus.

Lee MC, Rios AM, Aten MF, Mejias A, Cavuoti D, McCracken GH Jr, Hardy RD.

Pediatr Infect Dis J. 2004 Feb;23(2):123-7.

PMID:
14872177
17.

Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia.

Hardy RD, Rios AM, Chavez-Bueno S, Jafri HS, Hatfield J, Rogers BB, McCracken GH, Ramilo O.

Antimicrob Agents Chemother. 2003 May;47(5):1614-20.

18.

[The impact of antimicrobial resistance and Streptococcus pneumoniae serotype distribution on the mortality of children under 5 years of age with invasive disease].

Ríos AM, de la Hoz F, Leal AL, Castillo O, Castañeda E.

Rev Panam Salud Publica. 1999 Feb;5(2):69-76. Review. Spanish.

PMID:
10079739
19.

Repeated doses of the perfluorocarbon FC-100 improve lung function of preterm lambs.

Moya FR, Llanos AJ, Ríos AM, Riquelme RA, Moraga FA, Rubio LA, Salvo HD, Jacobs HC.

Pediatr Res. 1997 Dec;42(6):893-8.

PMID:
9396575
20.

[The utilization of health services and the motives for consultation as indicators of family dysfunction].

de la Revilla L, de los Ríos AM.

Aten Primaria. 1994 Feb 15;13(2):73-6. Spanish.

PMID:
8155796
21.

[Development of local health systems in Uruguay].

Noceti MC, Gherardi A, Ríos AM, Ríos F.

Bol Oficina Sanit Panam. 1990 Nov-Dec;109(5-6):556-9. Spanish.

PMID:
2151169
22.

CD9 is an unreliable antibody for bone marrow purging.

Fort JA, Rios AM, Gross S, Janssen WE.

Prog Clin Biol Res. 1990;333:185-9.

PMID:
2408060
23.

Immunomagnetic microsphere mediated purging of cALLa positive leukemic cells from bone marrow for autologous reinfusion.

Janssen WE, Lee C, Johnson KS, Spencer C, Rios AM, Graham-Pole JR, Gross S.

Prog Clin Biol Res. 1990;333:285-92.

PMID:
2137931
24.

Lipid coating of paramagnetic microspheres reduces non-specific binding to Kelly neuroblastoma cells.

Kedar A, Schreier H, Rios AM, Janssen WE, Gross S.

Prog Clin Biol Res. 1990;333:293-301.

PMID:
1689853
25.
26.

Clinical pharmacology of the biological response modifier maleic anhydride divinyl ether copolymer (MVE-2).

Rosenblum MG, Rios AM, Hersh EM.

Cancer Chemother Pharmacol. 1986;18(3):243-6.

PMID:
3802379
27.

Supplemental Content

Support Center